Antios Therapeutics, Inc   Report issue

For profit Phase 1 Phase 2
Founded: Atlanta GA United States (2018)

Organization Overview

First Clinical Trial
2020
NCT04248426
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Antios Therapeutics, Inc

Active Ingredients

Drugs in Phase 2 Trials (4)

ab-729 (1 trial)

ati-2173 (6 trials)

tenofovir (viread) (3 trials)

vebicorvir (1 trial)

Drugs in Phase 1 Trials (2)

clarithromycin (biaxin) (1 trial)

midazolam (versed) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis B (Phase 1)

Hepatitis B, Chronic (Phase 1)

Herpesviridae Infections (Phase 1)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 6